Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
6 evidence topics · 5 sources
Treat-to-target with endoscopic improvement and fecal calprotectin: ACG 2025
Monitoring schedule after starting advanced therapy: AGA 2024
“Initiation of advanced therapy should be followed by monitoring for symptomatic response within 3 months of initiation, symptomatic and biochemical remission within 3–6 months, and endoscopic improvement/ remission within 6–12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-treatment monitoring for potential toxicity from immunosuppressive therapies, such as periodic monitoring of hemogram, chemistries and transaminases, should be performed, according to drug label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treat-to-target, escalation, and multidisciplinary care: ECCO 2026
Therapeutic drug monitoring
Payer utilization management: ACG 2025 position
Pre-treatment screening required by labels of oral advanced therapies
Obefazimod-specific care management program
No evidence found.